New molecular clues on a neurodevelopmental disorder similar to Angelman syndrome

      -      spanish  -  english
The results highlight the RAF inhibition as a potential therapeutic target for n

The results highlight the RAF inhibition as a potential therapeutic target for neurosciences.

Angelman syndrome is a genetic disease that causes a developmental delay, alterations in speech and balance, intellectual disability and sometimes, seizures. To date, researchers had identified mutations in the HERC2 gene, which codes a ubiquitin ligase that plays a determining role in the nervous system. These mutations cause a hereditary neurodevelopmental disease which is similar to Angelman syndrome. The identified cases that are similar to Angelman syndrome have shown a total loss or very low levels of the HERC2.

Now, a research group led by Professor José Luís Rosa, from the Faculty of Medicine and Health Sciences of the UB and IDIBELL , has analysed the cellular signalling pathways affected by the most common mutation of the HERC2 gene (c.1781C>T, p.Pro594Leu) in this pathology. A better understanding of how the pathogenic variants affect these pathways will be decisive to help define potential therapies for this disease.

The results of the study, published in the journal Cellular and Molecular Life Sciences , show that the cells of those patients with this hereditary disease —or the human cells with a lack of HERC2 protein— have an overactivated cell response to oxidative stress, This is caused by an activation of an atypical signalling pathway in which the proteins RAF, MKK and p38 participate. "Our results highlight the RAF inhibition as a potential therapeutic target for people with this hereditary and neurodevelopmental disorder", concludes Professor José Luís Rosa.

Reference article:

Sala-Gaston, J. et al. ’HERC2 deficiency activates C-RAF/MKK3/p38 signalling pathway altering the cellular response to oxidative stres s’. Cellular and Molecular Life Sciences, October 2022. DOI: 10.1007/s00018’022 -04586-7


This site uses cookies and analysis tools to improve the usability of the site. More information. |